– UK, London – Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development innovation engine today announced the appointment of Dr. Mathias Hukkelhoven (Ph.D.) to its Board of Directors, effective July 1, 2022.
“I am very pleased to welcome Math to Centessa’s Board of Directors. Math’s deep industry experience in leading global regulatory and development efforts for novel therapeutics will be extremely valuable as we continue to advance our rare disease and immuno-oncology pipeline of potential best-in-class medicines for patients,” said CEO, Dr. Saurabh Saha.
Concurrently, the Company also announced the resignation of Aaron Kantoff from its Board effective July 1, 2022.
About Dr. Mathias Hukkelhoven
Dr. Hukkelhoven is an experienced global regulatory and drug development leader. He previously served as Senior Vice President, Global Regulatory, Safety & Biometrics at BMS and was also responsible for the R&D Group in BMS China and the Clinical Pharmacology and Pharmacometrics group. In these roles, Dr. Hukkelhoven was accountable for setting the regulatory strategy and driving the execution of global regulatory and pharmacovigilance plans for BMS. Before joining BMS, Dr. Hukkelhoven held the role of Chairman Portfolio Stewardship Board at Novartis Pharmaceutics and served as the Senior Vice President, Global Head Drug Regulatory Affairs at Novartis from 2001 to 2009. He also worked at Hoffmann LaRoche (Switzerland) and Organon (The Netherlands). Dr. Hukkelhoven has served as chairperson of the Regulatory Affairs Coordinating Committee at PhRMA, and recently as a PhRMA negotiator for the PDUFA VII negotiations with the U.S. Food and Drug Administration.
“I’m excited to join the Centessa Board at such a pivotal time for the Company,” commented Dr. Mathias Hukkelhoven. “I have been impressed by Centessa’s leadership team, vision, and exciting portfolio, and I look forward to working with the Board and the team to advance these potential therapies through proof of concept readouts with the ultimate goal of fulfilling unmet needs for patients.”
Dr. Hukkelhoven received his BS and Ph.D. with honors in Biology and Biochemistry from the University of Nijmegen, the Netherlands. Dr. Hukkelhoven also serves on the Board of Directors of Compugen Ltd and is a Senior Advisor to McKinsey and an R&D Strategy Advisor to LianBio.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company with an R&D innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology. We are led by a management team with extensive R&D experience, providing direct guidance to our program teams to rapidly advance our candidates from research through all stages of development.
For more information: https://centessa.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.